Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 7:33 PM ET


Company Overview of Reliance GeneMedix Limited

Company Overview

Reliance GeneMedix Limited, together with its subsidiaries, develops, manufactures, and distributes biotechnology pharmaceuticals. The company’s biosimilars are a generic version of recombinant therapeutic proteins. Its product under development includes EPOSTIM, a erythropoietin alpha that is used as a support therapy for the treatment of acute, chronic, and end-stage renal failure; in cancer-induced and chemotherapy related anemia; in patients undergoing major surgeries; and in AIDS patients on zidovudine treatment. The company is headquartered in Tullamore, Ireland. Reliance GeneMedix Limited is a subsidiary of Reliance Life Sciences Pvt. Ltd.

IDA Business & Technology Park




26 Employees


353 5 793 23572


353 5 793 23592

Key Executives for Reliance GeneMedix Limited

Chief Executive Officer and Company Secretary
Age: 47
Vice President of Operations
Age: 62
Executive Director
Age: 57
General Manager of Ireland Division
Age: 50
Director of Commercial Operations
Age: 49
Compensation as of Fiscal Year 2015.

Reliance GeneMedix Limited Key Developments

Reliance GeneMedix Wins GBP 230 Million Multiple Awardees Contract for Supplying Generic Pharmaceuticals

Reliance GeneMedix won GBP 230 million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit for the supply of generic pharmaceuticals. Potential periods of call-offs under the framework agreement: 100 % oral products: All regions 1.7.2015 to 28.2.2017 (20 months), 33 % hospital only products: DLN/DNW 1.7.2015 to 30.6.2017 (24 months), Housekeeping products: DLS/DNE 1.7.2015 to 29.2.2016 (8 months) and DCE/DSW 1.7.2015 to 31.10.2016 (16 months).

Similar Private Companies By Industry

Company Name Region
Druggability Technologies Holdings Limited Europe
Iterum Therapeutics Ltd. Europe
Opsona Therapeutics Limited Europe
Elan Capital Corp. Ltd. Europe
Labcoat Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Reliance GeneMedix Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at